Cardiovascular effects of the DPP-4 inhibitors
Diabetes and Vascular Disease Research, 2012 Type 2 Diabetes continues to rise in prevalence throughout the globe, and cardiovascular diseases remain the most common cause of morbidity and mortality among patients. Dipeptidyl-peptidase-4 (DPP-4) inhibitors are a newer class of oral anti-hyperglycemic agents whose effect is mediated through the incretin hormones, GLP-1 and GIP. In this review, we
Tessey, Jose, Silvio E, Inzucchi
openaire +2 more sources
What doesn't kill you makes you stranger: Dipeptidyl peptidase-4 (CD26) proteolysis differentially modulates the activity of many peptide hormones and cytokines generating novel cryptic bioactive ligands [PDF]
, 2019 Dipeptidyl peptidase 4 (DPP4) is an exopeptidase found either on cell surfaces where it is highly regulated in terms of its expression and surface availability (CD26) or in a free/circulating soluble constitutively available and intrinsically active form.
Aguilar-Pérez, Alexandra +13 more
core +1 more source
Molecules, 2018 Numerous studies indicate that diets with a variety of fruits and vegetables decrease the incidence of severe diseases, like diabetes, obesity, and cancer.
Poonam Kalhotra +3 more
doaj +1 more source
Localized JNK signaling regulates organ size during development. [PDF]
, 2016 A fundamental question of biology is what determines organ size. Despite demonstrations that factors within organs determine their sizes, intrinsic size control mechanisms remain elusive.
Beachy, Philip A +5 more
core +3 more sources
Indian Journal of Endocrinology and Metabolism, 2020 Background: Recent studies suggested that the increased risk of heart failure by DPP-4 inhibitors may have an interconnection with patients' baseline eGFR.
Maneesha Khalse, B Ganapathy
doaj +1 more source
Advances in Pharmacological and Pharmaceutical Sciences, 2023 Background. Recently, there is a lack of studies comparing the renoprotective effects of sodium-glucose cotransporter-2 (SGLT-2) inhibitors and dipeptidyl peptidase-4 (DPP-4) inhibitors.
Apichaya Chanawong +3 more
doaj +1 more source
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes [PDF]
, 2016 Background The cardiovascular effect of liraglutide, a glucagon-like peptide 1 analogue, when added to standard care in patients with type 2 diabetes, remains unknown. Methods In this double-blind trial, we randomly assigned patients with type 2 diabetes
Bergenstal, RM +15 more
core +1 more source
A cardiologic approach to non-insulin antidiabetic pharmacotherapy in patients with heart disease [PDF]
, 2009 Classical non-insulin antihyperglycemic drugs currently approved for the treatment of type 2 diabetes mellitus (T2DM) comprise five groups: biguanides, sulfonylureas, meglitinides, glitazones and alpha-glucosidase inhibitors.
Enrique Z Fisman, Alexander Tenenbaum
core +1 more source
Biliary effects of liraglutide and sitagliptin, a 12-week randomized placebo-controlled trial in type 2 diabetes patients [PDF]
, 2016 Aims: Treatment with glucagon-like peptide (GLP)-1 receptor agonists or dipeptidyl peptidase (DPP)-4 inhibitors might increase gallstone formation; however, the mechanisms involved are unknown. We aimed to assess the effects of these drugs on gallbladder
Cahen, D.L. (Djuna) +9 more
core +1 more source
The durability of oral diabetic medications: Time to A1c baseline and a review of common oral medications used by the primary care provider. [PDF]
, 2018 Introduction:Cost of generic medications has risen more in the past few years than any other time in history. While medical insurance covers much of these costs, health care professionals can better provide medications that have the longest duration of ...
Cherukuri, Lavanya +2 more
core